Regeneron Pharmaceuticals (REGN) Price Target Cut to $405.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by Cantor Fitzgerald from $441.00 to $405.00 in a research report report published on Monday morning, The Fly reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on REGN. Canaccord Genuity reiterated a hold rating and set a $353.00 price target (down previously from $408.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, May 8th. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $412.00 to $375.00 and set a market perform rating for the company in a research report on Wednesday, May 8th. UBS Group dropped their price target on Regeneron Pharmaceuticals from $480.00 to $440.00 and set a buy rating for the company in a research report on Wednesday, May 8th. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $420.00 to $389.00 and set an equal weight rating for the company in a research report on Wednesday, May 8th. Finally, Cowen reiterated a hold rating and set a $353.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 7th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $404.88.

REGN stock opened at $308.04 on Monday. The company has a quick ratio of 3.78, a current ratio of 4.58 and a debt-to-equity ratio of 0.08. The stock has a market cap of $33.42 billion, a price-to-earnings ratio of 15.56, a P/E/G ratio of 1.44 and a beta of 1.08. Regeneron Pharmaceuticals has a twelve month low of $291.10 and a twelve month high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). The company had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.76 billion. Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.67 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals will post 18.37 EPS for the current fiscal year.

In other news, EVP Neil Stahl sold 9,853 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the transaction, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at $14,507,363. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the transaction, the director now directly owns 11,323 shares in the company, valued at $3,464,045.39. The disclosure for this sale can be found here. Insiders sold 141,968 shares of company stock valued at $57,360,056 in the last quarter. Corporate insiders own 11.84% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of REGN. Whittier Trust Co. increased its stake in shares of Regeneron Pharmaceuticals by 195.7% during the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 45 shares during the period. Smithfield Trust Co. purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. AdvisorNet Financial Inc increased its stake in shares of Regeneron Pharmaceuticals by 208.0% during the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 52 shares during the period. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $29,000. Finally, Captrust Financial Advisors purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $30,000. 67.63% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Return on Equity (ROE)

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.